natgillin/translations-raw huggingface dataset:
• Keeping the vial on the table, attach water-filled syringe to vial adapter by holding the side of the vial adapter with one hand and twisting the syringe tip clockwise onto the adapter with the other hand until you feel a slight resistance. 
To naredite tako, da z eno roko držite stranski del nastavka za vialo, z drugo roko pa sučete konico brizge v smeri urnega kazalca v nastavek, dokler ne začutite rahlega upora.
Injection site haemorrhage Chest pain Irritability Malaise Face oedema Feeling hot Feeling jittery 
krvavitev na mestu injiciranja bolečine v prsih razdražljivost splošno slabo počutje edem obraza občutek vročine občutek živčnosti
Prepare new syringe for injection 
5. korak: Priprava nove brizge za injiciranje
ZIMULTI is taken as one tablet once a day, before breakfast. 
Zdravilo ZIMULTI se jemlje kot ena tableta enkrat dnevno pred zajtrkom.
The European Commission granted a marketing authorisation valid throughout the European Union for ZIMULTI to sanofi-aventis on 19 June 2006. 
Evropska komisija je dovoljenje za promet z zdravilom ZIMULTI, veljavno po vsej Evropski uniji, odobrila družbi sanofi-aventis dne 19. junija 2006.
The receptors are also found in adipocytes (fat tissue). 
Receptorji se nahajajo tudi v adipocitih (maščobnem tkivu).
The studies in smoking cessation did not show consistent results, and the effect of ZIMULTI in this area was difficult to estimate. 
Študije v zvezi s prenehanjem kajenja niso pokazale konsistentnih rezultatov, učinek zdravila ZIMULTI na tem področju pa je bilo težko oceniti.
Which measures are being taken to ensure the safe use of ZIMULTI? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila ZIMULTI?
Other information about ZIMULTI: 
Druge informacije o zdravilu ZIMULTI:
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil opravljene študije,, na podlagi katerih je oblikoval priporočila glede uporabe zdravila.
The company will use specific databases to monitor the side effects, especially those linked to the nervous system. 
Specifične zbirke podatkov bo podjetje uporabilo za spremljanje neželenih učinkov, zlasti tistih, povezanih z živčnim sistemom.
The medicine also reduced the risk of regaining weight. 
Zdravilo je tudi zmanjšalo tveganje za ponovno povečanje telesne mase.
The medicine should not be used in patients who have severe problems with their liver or their kidneys. 
Zdravila ne smejo jemati bolniki, ki imajo hude težave z jetri ali ledvicami.
The effects of ZIMULTI were first tested in experimental models before being studied in humans. 
Učinki zdravila ZIMULTI so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The patients should also follow a reduced calorie diet and increase their level of physical activity. 
Poleg tega morajo bolniki slediti dieti z zmanjšano vsebnostjo kalorij in povečati fizično aktivnost.
The company decided to withdraw its application for smoking cessation. 
Podjetje se je odločilo, da umakne vlogo za uporabo zdravila pri prenehanju kajenja.
Patients who experience symptoms of depression should speak to their doctor and may need to stop treatment. 
Bolniki, pri katerih se pojavi depresija, se morajo pogovoriti z zdravnikom, zdravljenje pa bo morda porebno prekiniti.
The active substance in ZIMULTI, rimonabant, is a cannabinoid receptor antagonist. 
Zdravilna učinkovina v zdravilu ZIMULTI, rimonabant, je antagonist kanabinoidnih receptorjev.
• who are obese (very overweight) with a body mass index (BMI) greater than or equal to 30 kg/m², 
• so debeli (z zelo prekomerno telesno maso) s indeksom telesne mase (BMI) večjim ali enakim 30 kg/m², ali
After one year, all patients who received ZIMULTI lost more weight than those who received placebo: they lost on average 4.9 kg more than placebo, except in the study in diabetic patients, where the difference in the weight loss was 3.9 kg. 
Po enem letu se je pri bolnikih, ki so prejemali zdravilo ZIMULTI telesna masa zmanjšala bolj kot pri tistih, ki so prejemali placebo: povprečno so izgubili 4,9 kg več kot s placebom, razen v študiji z diabetičnimi bolniki, kjer je bila razlika v zmanjšanju telesne mase 3,9 kg.
Therefore, ZIMULTI is not recommended as an aid for smoking cessation 
Zdravilo ZIMULTI torej kot pomoč pri prenehanju kajenja ni priporočeno.
Caution should be used when taking ZIMULTI with some medicines, such as ketoconazole or itraconazole (anti-fungal medicines), ritonavir (used in HIV infection), or telithromycin or clarithromycin (antibiotics). 
Pri sočasnem jemanju zdravila ZIMULTI in nekaterih drugih zdravil, kot so ketokonazol ali itrakonazol (zdravili proti glivicam), ritonavir (ki se uporablja pri okužbi s HIV), telitromicin ali klaritromicin (antibiotika) je potrebna previdnost.
What benefit has ZIMULTI shown during the studies? 
Kakšne koristi je zdravilo ZIMULTI izkazalo med raziskavami?
The company that makes ZIMULTI will put in place a programme to ensure that the medicine is used in patients who need it for health, rather than for cosmetic reasons, by providing educational packs for patients and doctors, and to monitor how the medicine is used. 
Podjetje, ki izdeluje zdravilo ZIMULTI bo pripravilo program z izobraževalnim gradivom za bolnike zdravnike, s katerim bo zagotovilo, da se zdravilo uporablja pri bolnikih, ki ga potrebujejo zaradi zdravja in ne iz kozmetičnih razlogov, ter bo nadzorovalo njegovo uporabo.
ZIMULTI is a medicine containing the active substance rimonabant. 
ZIMULTI so zdravilo, ki vsebuje zdravilno učinkovino rimonabant.
What is the risk associated with ZIMULTI? 
Kakšna tveganja so povezana z zdravilom ZIMULTI?
It is available as white, teardropshaped tablets. 
Na voljo je v obliki tablet bele barve, ki imajo obliko solze.
Why has ZIMULTI been approved? 
Zakaj je bilo zdravilo ZIMULTI odobreno?
©EMEA 2007 
Zdravilo nima veā dovoljenja za promet©EMEA 2007
ZIMULTI should not be used in patients who may be hypersensitive (allergic) to rimonabant or any of the other ingredients, or in women who are breast feeding. 
Zdravila ZIMULTI ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) rimonabant ali katero koli drugo sestavino zdravila ter ženske, ki dojijo.
The Committee recommended that ZIMULTI be given marketing authorisation. 
Odbor je priporočil odobritev dovoljenja za promet z zdravilom ZIMULTI.
The Committee decided that ZIMULTI's benefits are greater than its risks when used, in addition to diet and exercise, to treat obese patients and overweight patients with risk factors such as type 2 diabetes or dyslipidaemia. 
Odločil je da so koristi zdravila ZIMULTI večje od z njim povezanih tveganj, kadar se uporablja kot dodatek k dieti in telesni dejavnosti pri zdravljenju debelih bolnikov in bolnikov s čezmerno telesno maso z dodatnimi dejavniki tveganja kot so diabetes tipa 2 ali dispidemija.
The Committee for Medicinal products for Human Use (CHMP) concluded that ZIMULTI had shown its effectiveness in weight reduction in obese or overweight patients with associated risk factors. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je sklenil, da je zdravilo ZIMULTI izkazalo učinkovitost pri zmanjšanju telesne mase pri debelih bolnikih in bolnikih s čezmerno telesno maso, pri katerih obstajajo dodatni dejavniki tveganja.
During the studies, the most common side effects with ZIMULTI (seen in more than 1 patient in 10) were nausea (feeling sick) and infections of the upper respiratory tract. 
Neželeni učinki zdravila ZIMULTI, ki so bili med študijami najpogosteje opaženi (pri več kot 1 od 10 bolnikov), so navzeja (občutek slabosti) in okužbe zgornjih dihal.
ZIMULTI is used together with diet and exercise to treat adult patients: 
Zdravilo ZIMULTI se kot dodatek k dieti in telesni dejavnosti uporablja za zdravljenje odraslih bolnikov, ki:
The studies compared the effect of ZIMULTI with that of a placebo (a dummy treatment) on weight loss over one to two years. 
V študijah so primerjali učinek zdravila ZIMULTI z učinkom placeba (zdravila brez zdravilne učinkovine) na zmanjšanje telesne mase v enem do dveh let.
Four studies of ZIMULTI in overweight and obese patients were carried out, involving almost 7,000 patients, whose weight at the start of the studies was on average 94 to 104 kg. One study looked more particularly at patients with abnormal levels of blood fat, and one at patients with type 2 diabetes. 
Zdravilo ZIMULTI je bilo raziskano v štirih študijah, v katerih je sodelovalo skoraj 7000 debelih bolnikov in bolnikov s čezmerno telesno maso, katerih teža je bila na začetku študij povprečno med 94 in 104 kg.
For the full list of all side effects reported with ZIMULTI, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila ZIMULTI, glejte Navodilo za uporabo.
What is ZIMULTI used for? 
Za kaj se zdravilo ZIMULTI uporablja?
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ZIMULTI EPAR summary for the public 
Povzetek EPAR za javnost
It acts by blocking a specific type of receptors, the cannabinoid type 1 (CB1) receptors. 
Deluje tako, da blokira specifično vrsto receptorjev, kanabinoidnih receptorjev tipa 1 (CB1), ki se nahajajo v živčnem sistemu in so del sistema, ki ga telo uporablja za nadzor vnosa hrane.
One study also looked at how this loss could be maintained during the second year. 
doseženo zmanjšanje telesne mase obdržati tekom drugega leta.
Four studies of ZIMULTI as a help to stop smoking were also carried out in over 7,000 patients, comparing it with placebo, and measuring the effect of the medicine given for 10 weeks (one year in one of the studies) on smoking cessation, and on relapses in the following year. 
Zdravilo so primerjali s placebom in merili učinek zdravila, uporabljanega 10 tednov (eno leto v eni od študij), na prenehanje kajenja ter na ponoven začetek kajenja v naslednjem letu.
It must also not be used in patients with ongoing major depression or who are being treated with antidepressants, since it can increase the risk of depression, including thoughts about suicide in a small minority of patients. 
Zdravilo lahko poveča tveganje za depresijo, vključno s samomorilnimi mislimi pri majhnem številu bolnikov, zato se ne sme uporabljati pri bolnikih s trenutno potekajočo veliko depresivno motnjo ali bolnikih, ki se zdravijo z antidepresivi.
How does ZIMULTI work? 
Kako zdravilo ZIMULTI deluje?
How has ZIMULTI been studied? 
Kako je bilo zdravilo ZIMULTI raziskano?
How is ZIMULTI used? 
Kako se zdravilo ZIMULTI uporablja?
The full EPAR for ZIMULTI can be found here. 
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo ZIMULTI je na voljo tukaj.
• who are overweight (with a BMI greater than or equal to 27 kg/m²) and also have other risk factors, 
• imajo čezmerno telesno maso (BMI večji ali enak 27 kg/m²) in pri katerih obstajajo dodatni dejavniki tveganja, kot so na primer diabetes tipa 2 ali dislipidemija (nenormalne ravni maščobe v krvi).
What is ZIMULTI? 
Kaj je zdravilo ZIMULTI?
The Member States shall ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented: 
Države članice morajo zagotoviti, da se izvajajo vsi spodaj opisani pogoji ali omejitve v zvezi z varno in učinkovito uporabo zdravila:
The Member States shall agree the details educational materials with the MAH according to national regulations and healthcare systems and ensure that it is implemented nationally so that all health care professionals who intend to prescribe and/or dispense PhotoBarr are provided with the following: 
Države članice se morajo o podrobni vsebini izobraževalnih gradiv dogovoriti z imetnikom dovoljenja za promet z zdravilom v skladu z nacionalnimi predpisi in sistemom zdravstvenega varstva ter zagotoviti njihovo uvedbo na nacionalni ravni tako, da ima strokovno zdravstveno osebje, ki bo predpisovalo zdravilo PhotoBarr in/ali delalo z njim, na voljo naslednje:
− You should not be treated with PhotoBarr if you have severe liver disease (eg cirrhosis) 
− Zdravljenja s PhotoBarrom ne smete prejemati, če imate hudo okvaro jeter (npr. cirozo).
− The educational tools are designed to aid physicians in optimising the benefit-risk ratio of porfimer treatment. 
− Izobraževalna orodja so namenjena zdravnikom za optimiziranje razmerja koristi in
− Brief background and introduction to Barrett's oesophagus and high grade dysplasia 
Navodila za bolnike − Kratek opis in razlaga Barretovega požiralnika ter visoke stopnje displazije
o Commercially available sun blocks are not effective in preventing sensitivity due to 
o običajna komercialna sredstva za zaščito pred soncem niso učinkovita v preprečevanju preobčutljivosti.
− Area in card for physician to record skin type and date of injection. 
− V bolnikovo kontrolno izkaznico vnesite tip kože in datum injiciranja zdravila.
• Healthcare professionals administration and monitoring guide 
• Navodila za zdravstveno osebje za pripravo zdravila in ravnanje z njim
o all patients should know that UV blocking is not effective in blocking visible light o Patients should be aware of potential risk factors (skin phototype and hepatic o Patients should be instructed to seek medical advice if signs/symptoms suggestive of photosensitivity occur during or after therapy with porfimer. 
o Bolniki morajo biti seznanjeni z možnimi nevarnostmi (fototip kože in okvare o Bolnike je treba poučiti, da se v primeru, da se med ali po zdravljenju s porfirini pojavijo fotosenzitivne reakcije, posvetujejo z zdravnikom.
Healthcare professional's administration and monitoring guide 
Navodila za zdravstveno osebje za pripravo zdravila in ravnanje z njim ter izobraževalno gradivo
− Patients should NOT be treated with porfimer if: o they have severe hepatic disease. 
− Bolnikov se NE sme zdraviti s porfirini, če:
• Prescriber guide 
• Predstavitveno izobraževalno gradivo
− It is important that patients tell their doctor if they get exposed to sunlight after receiving treatment with PhotoBarr. 
− Pomembno je, da bolniki opozorijo zdravnika, če so bili po zdravljenju s
− Before initiating therapy, o The patient should be screened for skin type o Patients should be aware of the long half-life of porfimer and that the compound gets o Patients should avoid being exposed to light for 60-90 days post-exposure. 
− Bolniki morajo zdravnika pred pričetkom zdravljenja obvestiti o morebitni hudi o se v telesu zadržuje 60-90 dni po prejemu injekcije.
Patient alert card − The need to show this card to any doctor treating them photosensitivity are possible o Commercially available sun blocks are not effective in preventing sensitivity due to light o Photosensitivity can only be prevented by avoiding exposure to the sun for 90 days after receiving the PhotoBarr injection 
o se preobčutljivost na svetlobo lahko prepreči samo, če se bolnik izogiba neposredni izpostavljenosti svetlobi 90 dni po injiciranju PhotoBarra.
− What photodynamic therapy is 
o se PhotoBarr aktivira z vidno svetlobo.
− Patients should inform their doctor before they start treatment if they have severe hepatic disease. 
− Bolnikom je treba pojasniti, da morajo to kartico pokazati svojim lečečim zdravnikom.
This overview was last updated in March 2019. 
Ta pregled je bil nazadnje posodobljen marca 2019.
Further information on Baycox Iron can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/baycox-iron. 
Nadaljnje informacije o zdravilu Baycox Iron so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPAR/baycox-iron.
As a result it is able to kill the parasites at all stages of their development and prevent the symptoms of coccidiosis and the spread of infection. 
Posledično lahko parazite uniči na vseh razvojnih stopnjah ter prepreči simptome kokcidioze in širjenje okužbe.
It is given as a single injection into the muscle behind the ear of piglets between 48 and 72 hours old. 
Daje se v obliki enkratne injekcije v mišico za uhljem pujskov, starih med 48 in 72 ur.
The European Medicines Agency decided that Baycox Iron's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Baycox Iron večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
The withdrawal period for meat from pigs treated with Baycox Iron is 53 days. 
Karenca za meso prašičev, zdravljenih z zdravilom Baycox Iron, je 53 dni.
Baycox Iron may be harmful for the unborn child. 
Zdravilo Baycox Iron je lahko škodljivo za nerojene otroke.
Iron is an essential nutrient needed to make haemoglobin to transport oxygen in the blood, as well as certain key enzymes, and without additional iron, piglets raised under intensive farming conditions will develop anaemia within 10 days after birth. 
Železo je pomembno hranilo, ki je potrebno, da hemoglobin prenaša kisik v krvi in nekatere ključne encime, brez dodatnega železa pa pujski, vzrejeni v pogojih intenzivnega kmetovanja, anemijo razvijejo v 10 dneh po rojstvu.
Baycox Iron received a marketing authorisation valid throughout the EU on 20 May 2019. 
Za zdravilo Baycox Iron je bilo 20. maja 2019 izdano dovoljenje za promet, veljavno po vsej Evropski uniji.
Following injection into the muscle, gleptoferron is absorbed and broken down to release iron for use and/or storage depending on the need for iron in suckling piglets. 
Gleptoferon se po injiciranju v mišico absorbira in presnavlja z namenom, da sprosti železo za uporabo in/ali shranjevanje, odvisno od potrebe sesnih pujskov po železu.
People who are hypersensitive (allergic) to iron compounds or toltrazuril should avoid contact with Baycox Iron. 
Ljudje, ki so preobčutljivi za (alergični na) železove spojine ali toltrazuril, se morajo izogibati stiku z zdravilom Baycox Iron.
Toltrazuril is an antiparastic medicine which interferes with the enzymes needed by coccidia parasites to produce energy. 
Toltrazuril je antiparazitik, ki vpliva na encime, ki jih paraziti kokcidije potrebujejo za tvorbo energije.
In a field study performed in 3 EU countries and involving 968 piglets on farms with a history of coccidiosis, a single intramuscular injection of Baycox Iron given at 3 days of age was effective in preventing iron deficiency anaemia, and reducing oocyst excretion and diarrhoea associated with coccidiosis caused by the coccidia parasite Cystoisospora suis, in comparison with giving iron only (as gleptoferron) at 3 days of age. 
V terenski študiji, ki je bila izvedena v treh državah članicah EU in je vključevala 968 pujskov na farmah, na katerih se je v preteklosti že pojavila parazitska okužba kokcidioza, se je izkazalo, da je enkratna intramuskularna injekcija zdravila Baycox Iron, ki se daje pri starosti tri dni, učinkovita pri preprečevanju anemije zaradi pomanjkanja železa ter zmanjšanju izločanja oocist in driske, povezane s kokcidiozo, ki jo povzroča parazit Cystoisospora suis, v primerjavi z dajanjem samo železa (v obliki gleptoferona) pri starosti tri dni.
The most common side effects with Baycox Iron (which may affect up to 1 in 10 piglets) are short-lived tissue discolouration and slight swelling at the injection site. 
Najpogostejši neželeni učinki zdravila Baycox Iron (ki se lahko pojavijo pri največ 1 od 10 pujskov) so kratkotrajno razbarvanje tkiva in blaga oteklina na mestu injiciranja.
Baycox Iron must not be given to piglets suspected to have insufficient levels of vitamin E or selenium. 
Zdravilo Baycox Iron se ne sme dajati pujskom, pri katerih obstaja sum pomanjkanja vitamina E ali selena.
For more information about using Baycox Iron, see the package leaflet or contact your veterinarian or pharmacist. 
Za več informacij glede uporabe zdravila Baycox Iron glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
Other information about Baycox Iron 
Druge informacije o zdravilu Baycox Iron
Baycox Iron is also used to reduce spread of the infection through passage of oocysts in faeces, and at the same time to prevent iron deficiency anaemia due to the limited iron reserves of new-born piglets, low iron content of milk and high growth rate of suckling piglets. 
Zdravilo Baycox Iron se uporablja tudi za zmanjšanje širjenja okužbe prek oocist v iztrebkih in sočasno za preprečevanje anemije zaradi omejenih rezerv železa pri novorojenih pujskih, nizke vsebnosti železa v mleku in hitre rasti sesnih pujskov.
It is used in young piglets on farms which have been affected in the past by the parasitic infection coccidiosis to prevent diarrhoea caused by a new coccidiosis infection. 
Uporablja se pri pujskih na farmah, na katerih se je v preteklosti že pojavila parazitska okužba kokcidioza, za preprečevanje driske, ki jo povzroči nova okužba s kokcidiji.
Baycox Iron is a veterinary medicine. 
Baycox Iron je zdravilo za uporabo v veterinarski medicini.
Why is Baycox Iron authorised in the EU? 
Zakaj je zdravilo Baycox Iron odobreno v EU?
Infected piglets shed disease spores (oocysts) in their faeces that can spread the infection. 
Okuženi pujski z iztrebki izločajo bolezenske spore (oociste), ki lahko širijo okužbo.
Coccidiosis is a disease of the gut which results in reduced growth due to diarrhoea. 
Kokcidioza je črevesna bolezen, za katero je značilen zastoj rasti zaradi driske.
For the full list of side effects and restrictions of Baycox Iron, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Baycox Iron glejte navodilo za uporabo.
An overview of Baycox Iron and why it is authorised in the EU 
Pregled zdravila Baycox Iron in zakaj je odobreno v EU
What is Baycox Iron and what is it used for? 
Kaj je zdravilo Baycox Iron in za kaj se uporablja?
Baycox Iron is available as an injection and can only be obtained with a prescription. 
Zdravilo Baycox Iron je na voljo v obliki injekcije, njegovo predpisovanje in izdaja pa je le na recept.
What are the risks associated with Baycox Iron? 
Kakšna tveganja so povezana z zdravilom Baycox Iron?
What benefits of Baycox Iron have been shown in studies? 
Kakšne koristi je zdravilo Baycox Iron izkazalo v študijah?
The other active substance in Baycox Iron, gleptoferron, is an iron-containing compound. 
Druga učinkovina v zdravilu Baycox Iron, gleptoferon, je spojina, ki vsebuje železo.
Baycox Iron contains the active substances toltrazuril and gleptoferron (an iron-containing compound). 
Zdravilo Baycox Iron vsebuje učinkovini toltrazuril in gleptoferon (spojina, ki vsebuje železo).
How does Baycox Iron work? 
Kako zdravilo Baycox Iron deluje?
How is Baycox Iron used? 
Kako se zdravilo Baycox Iron uporablja?
Applicant company name, address 
Ime, naslov podjetja predlagatelja
Mentocaína Spray 8.75 mg/dose Oromucosal spray, solution 
Mentocaína Spray 8,75 mg/ odmerek
Check with your doctor. 
Posvetujte se s svojim zdravnikom.
Unopened vial: 2 years. 
Neodprta viala: 2 leti.
More than half of the responses were apparent after the first three cycles of treatment. 
Več kot pol odzivov je bilo očitnih po prvih treh krogih zdravljenja.
• Ringing in your ears 
• zvonjenje v ušes
Each infusion contains up to 21 g of alcohol. 
Vsaka infuzija zdravila vsebuje do 21 g alkohola.
These agents are used to treat cancer. 
Ta zdravila se uporabljajo za zdravljenje raka.
• Bad taste in your mouth 
• slab okus v ustih
• are taking other medicines that you have bought for yourself without a prescription. 
• jemljete druga zdravila, ki ste jih kupili brez recepta.
The use of gloves, goggles and protective clothing is recommended. 
Priporočljiva je uporaba rokavic, zaščitnih očal in oblek.
For each of these parameters, the increases were severe in 1% of cases. 
Do hujšega povečanja pri vsakem od teh parametrov je prišlo v 1 % primerov.
• Painful sensation in the body 
• boleč občutek v telesu
19 % of patients had severe neutropenia for > 7 days. 
19 % bolnikov je imelo hudo nevtropenijo > 7 dni.
Date of first authorisation: 19th July 1999. 
Datum pridobitve dovoljenja za promet: 19. julij 1999.
Patients should be observed closely during the initial cycles of treatment. 
Bolnike je potrebno v začetnih ciklih zdravljenja natančno opazovati.